Federal contract award
75A50123C00052
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 611310 — Colleges, Universities, and Professional Schools |
| PSC | Q701 — Specialized Medical Support |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $8.4M |
| Current contract value | $8.4M |
| Potential contract value / ceiling | $8.4M |
| Start date | Sep 21, 2023 |
| Current end date | Sep 30, 2027 |
| Potential end date | Sep 30, 2027 |
| Latest award activity | Jul 27, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 27, 2026 | P00007 | $2.0M | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Dec 17, 2025 | P00006 | $0 | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Jun 26, 2025 | P00005 | $2.1M | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Mar 27, 2025 | P00004 | $502.4K | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Feb 26, 2025 | P00003 | $0 | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Aug 29, 2024 | P00002 | $0 | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Jun 12, 2024 | P00001 | $1.1M | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
| Sep 21, 2023 | 0 | $2.7M | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE DEVELOPMENT AND VALIDATION OF BIOTIN AS AN IN VIVO LABELLING AGENT FOR RED BLOOD CELLS TO REPLACE CHROMIUM 51 AS THE STANDARD FDA-APPROVED TECHNOLOGY FOR ASSESSING THE LIFESPAN OF RBCS IN CIRCULATION. |
Estimated positioning window
Nov 1, 2026 – Mar 30, 2027
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2027-09-30 (333 days from calculation)
- +35 points
- 1 historical awards in this buyer and category group
- +0 points
- 8 recorded award transactions
- +10 points
- Latest award action: 2026-07-27
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.